Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NamePrednisolone
Accession NumberDB00860  (APRD00197)
Typesmall molecule
Groupsapproved
Description

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
delta-dehydrocortisolNot AvailableNot Available
delta-dehydrohydrocortisoneNot AvailableNot Available
delta-hydrocortisoneNot AvailableNot Available
HydroretrocortineNot AvailableNot Available
MetacortandraloneNot AvailableNot Available
PRDLNot AvailableNot Available
PrednisolonaSpanishINN
PrednisolonumLatinINN
Salts
Name/CAS Structure Properties
Predisolone Sodium Phosphate
125-02-0
Thumb
  • InChI Key: VJZLQIPZNBPASX-WFFZFITINA-L
  • Monoisotopic Mass: 484.123893702
  • Average Mass: 484.3876
DBSALT000785
Prednisolone Acetate
Thumb
  • InChI Key: LRJOMUJRLNCICJ-JZYPGELDSA-N
  • Monoisotopic Mass: 402.204238692
  • Average Mass: 402.4807
DBSALT000254
Prednisolone Tebutate
7681-14-3
Thumb
  • InChI Key: HUMXXHTVHHLNRO-KAJVQRHHSA-N
  • Monoisotopic Mass: 458.266838948
  • Average Mass: 458.587
DBSALT000786
Brand names
NameCompany
Ak-PredNot Available
Decortin HNot Available
Delta-CortefNot Available
DeltacortrilNot Available
HydeltraNot Available
Hydeltra-TBANot Available
HydeltrasolNot Available
InflamaseNot Available
Key-PredNot Available
KlismacortNot Available
MeticorteloneNot Available
OrapredNot Available
PanafcorteloneNot Available
PediapredNot Available
PrecortalonNot Available
PredonineNot Available
PreloneNot Available
SoloneNot Available
SteroloneNot Available
UltracortenolNot Available
Brand mixtures
Brand NameIngredients
Ak Cide Oph SolnPrednisolone Acetate + Sulfacetamide Sodium
Blephamide Oph OntPrednisolone Acetate + Sulfacetamide Sodium
Blephamide Opht SuspensionPrednisolone Acetate + Sulfacetamide Sodium
CanauralDiethanolamine Fusidate + Framycetin Sulfate + Nystatin + Prednisolone
ChlorasoneChloramphenicol + Prednisolone Acetate
Delta-Albaplex TabletsNovobiocin (Novobiocin Sodium) + Prednisolone + Tetracycline Hydrochloride
Dioptimyd OintmentPrednisolone Acetate + Sulfacetamide Sodium
Dioptimyd SuspensionPrednisolone Acetate + Sulfacetamide Sodium
LiquichlorChloramphenicol + Prednisolone + Squalane + Tetracaine
Metimyd Oph SusPrednisolone Acetate + Sulfacetamide Sodium
OptisoneNeomycin + Prednisolone
Pred C TabAluminum Hydroxide + Prednisolone + Salicylamide + Vitamin C
Prednisize SolutionCamphor + Chlorophenol + Cresyl Acetate + Prednisolone
Quiex-Pred SusAminophylline + Guaifenesin + Prednisolone
Surolan DropsMiconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate
Vanectyl-P TabletsPrednisolone + Trimeprazine Tartrate
Vasocidin Ophthalmic SolutionPrednisolone Sodium Phosphate + Sulfacetamide Sodium
Categories
CAS number50-24-8
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyInChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsKetosteroids; Hydroxysteroids; Cyclohexanols; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Enolates; Polyamines; Primary Alcohols; Aldehydes
Substituents3-keto-steroid; 11-hydroxy-steroid; 17-hydroxy-steroid; 20-keto-steroid; cyclohexanol; tertiary alcohol; cyclic alcohol; secondary alcohol; ketone; primary alcohol; enolate; polyamine; alcohol; carbonyl group; aldehyde
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
Pharmacology
IndicationFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
PharmacodynamicsPrednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Mechanism of actionGlucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
AbsorptionReadily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Volume of distributionNot Available
Protein bindingVery high (>90%)
Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Prednisone Action PathwayDrug actionSMP00440
Prednisolone Action PathwayDrug actionSMP00441
Prednisone Metabolism PathwayDrug metabolismSMP00631
Prednisolone Metabolism PathwayDrug metabolismSMP00632
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9918
Blood Brain Barrier + 0.9383
Caco-2 permeable - 0.5096
P-glycoprotein substrate Substrate 0.7861
P-glycoprotein inhibitor I Non-inhibitor 0.7847
P-glycoprotein inhibitor II Non-inhibitor 0.8383
Renal organic cation transporter Non-inhibitor 0.7463
CYP450 2C9 substrate Non-substrate 0.8496
CYP450 2D6 substrate Non-substrate 0.9138
CYP450 3A4 substrate Substrate 0.7407
CYP450 1A2 substrate Non-inhibitor 0.9406
CYP450 2C9 substrate Non-inhibitor 0.9072
CYP450 2D6 substrate Non-inhibitor 0.9418
CYP450 2C19 substrate Non-inhibitor 0.9253
CYP450 3A4 substrate Non-inhibitor 0.8902
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9095
Ames test Non AMES toxic 0.9132
Carcinogenicity Non-carcinogens 0.9597
Biodegradation Not ready biodegradable 0.925
Rat acute toxicity 1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.95
hERG inhibition (predictor II) Non-inhibitor 0.584
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
LiquidOral
SolutionOral
Solution / dropsOphthalmic
SuspensionOphthalmic
TabletOral
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USDbox
Pred Forte 1% Suspension 15ml Bottle97.79USDbottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USDbottle
Pred Forte 1% Suspension 10ml Bottle68.06USDbottle
Econopred Plus 1% Suspension 10ml Bottle63.44USDbottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USDvial
Solu-Medrol 1 g/vial60.04USDvial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USDbottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USDbottle
Econopred Plus 1% Suspension 5ml Bottle40.99USDbottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USDvial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USDdisp
Solu-Medrol 500 mg/vial39.17USDvial
Pred Forte 1% Suspension 5ml Bottle37.12USDbottle
Prednisolone sod ph powder36.11USDg
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USDbottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USDbottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USDbottle
Methylprednisolone Sod Succin. 1 g/vial32.47USDvial
Solu-medrol 1 gm vial24.43USDvial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USDbottle
Solu-medrol (pf) 500 mg vial20.9USDvial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USDbottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USDvial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USDbottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USDvial
Solu-medrol 500 mg vial12.9USDvial
Depo-medrol 80 mg/ml vial11.67USDml
Depo-Medrol 80 mg/ml11.51USDml
Pred forte 1% eye drops10.32USDml
Methylprednisolone Acetate 80 mg/ml9.01USDml
Methylprednisolone Sod Succin. 125 mg/vial8.9USDvial
Depo-Medrol (Preserved) 80 mg/ml8.89USDml
Orapred odt 30 mg tablet8.34USDtablet
Orapred odt 15 mg tablet7.97USDtablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USDml
Omnipred 1% eye drops6.78USDml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USDvial
Depo-medrol 40 mg/ml vial6.41USDml
Depo-Medrol 40 mg/ml6.01USDml
Pred Forte 1 % Suspension5.95USDml
Solu-medrol (pf) 125 mg vial5.83USDvial
Depo-Medrol (Preserved) 40 mg/ml5.75USDml
Prednisolone ac 1% eye drop5.75USDml
Prednisol 1% eye drops5.69USDml
Pred mild 0.12% eye drops5.14USDml
Medrol 32 mg tablet5.13USDtablet
Methylprednisolone Acetate 40 mg/ml4.71USDml
Methylprednisolone Acetate (P) 40 mg/ml4.5USDml
Econopred plus 1% eye drops3.93USDml
Orapred odt 10 mg tablet3.89USDtablet
Depo-medrol 20 mg/ml vial3.78USDml
Methylprednisolone Sod Succin. 40 mg/vial3.77USDvial
Prednisolone sod 1% eye drops3.7USDml
Medrol 16 mg tablet3.5USDtablet
Prednisolone acetate powder3.36USDg
Prednisolone powder3.36USDg
Depo-Medrol 20 mg/ml2.63USDml
Medrol 8 mg tablet2.3USDtablet
Ratio-Prednisolone 1 % Suspension2.03USDml
Sandoz Prednisolone Acetate 1 % Suspension2.03USDml
Pred Mild 0.12 % Suspension2.02USDml
Medrol 4 mg tablet1.69USDtablet
Medrol 4 mg dosepak1.59USDeach
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USDml
Millipred dp 5 mg dose pack tablet1.18USDtablet
Medrol 2 mg tablet0.84USDtablet
Orapred 15 mg/5 ml solution0.74USDml
Millipred 5 mg tablet0.59USDtablet
Prelone 15 mg/5 ml syrup0.54USDml
Prelone 15 mg/5ml Syrup0.47USDml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USDml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USDml
Prednisolone 5 mg tablet0.14USDtablet
Pediapred 1 mg/ml Liquid0.14USDml
Pms-Prednisolone 1 mg/ml Liquid0.07USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States67403411999-11-242019-11-24
United States51788781993-01-122010-01-12
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
water solubility2.39e-01 g/lALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (strongest acidic)12.58ChemAxon
pKa (strongest basic)-2.9ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count5ChemAxon
hydrogen donor count3ChemAxon
polar surface area94.83ChemAxon
rotatable bond count2ChemAxon
refractivity98.49ChemAxon
polarizability38.78ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Gunther Bellmann, “Process for producing a sterile prednisolone gel.” U.S. Patent US5811417, issued September 22, 1998.

US5811417
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00472
KEGG CompoundC07369
PubChem Compound5755
PubChem Substance46504847
ChemSpider5552
BindingDB19190
ChEBI8378
ChEMBLCHEMBL131
Therapeutic Targets DatabaseDAP000419
PharmGKBPA451096
IUPHAR2866
Guide to Pharmacology2866
Drug Product Database2245532
RxListhttp://www.rxlist.com/cgi/generic/prednisolone.htm
Drugs.comhttp://www.drugs.com/cdi/prednisolone-acetate-drops.html
WikipediaPrednisolone
ATC CodesA07EA01C05AA04D07AA01D07AA03D07AC14D07XA02D10AA02H02AB04H02AB06R01AD02S01BA04S01CB02S02BA03S03BA02
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelshow(101 KB)
MSDSshow(72.6 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe corticosteroid, prednisolone, alters the anticoagulant effect, acenocoumarol.
Acetylsalicylic acidThe corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.
AmbenoniumThe corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, ambenonium.
AmobarbitalThe barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisolone.
AnisindioneThe corticosteroid, prednisolone, alters the anticoagulant effect of anisindione.
AprobarbitalThe barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisolone.
Bismuth SubsalicylateThe corticosteroid, prednisolone, may decrease the effect of the salicylate, bismuth subsalicylate.
ButabarbitalThe barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone.
ButalbitalThe barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone.
ButethalThe barbiturate, butethal, may decrease the effect of the corticosteroid, prednisolone.
ChlorotrianiseneThe estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone.
ClomifeneThe estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone.
Conjugated EstrogensThe estrogenic agent may increase the effect of the corticosteroid, prednisolone.
DicoumarolThe corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol.
DiethylstilbestrolThe estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone.
Dihydroquinidine barbiturateThe barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
EdrophoniumThe corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium.
EstradiolThe estrogenic agent, estradiol, may increase the effect of the corticosteroid, prednisolone.
EstriolThe estrogenic agent, estriol, may increase the effect of the corticosteroid, prednisolone.
EstroneThe estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone.
EstropipateThe estrogenic agent, estropipate, may increase the effect of the corticosteroid, prednisolone.
Ethinyl EstradiolThe estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone.
EthotoinThe enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone.
FosphenytoinThe enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone.
HeptabarbitalThe barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisolone.
HexobarbitalThe barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisolone.
ItraconazoleThe imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
KetoconazoleThe imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
Magnesium salicylateThe corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
MephenytoinThe enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisolone.
MestranolThe estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone.
MethohexitalThe barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone.
MethylphenobarbitalThe barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisolone.
MidodrineIncreased arterial pressure
NeostigmineThe corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine.
PentobarbitalThe barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone.
PhenobarbitalThe barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone.
PhenytoinThe enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone.
PrimidoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone.
PyridostigmineThe corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
QuinestrolThe estrogenic agent, quinestrol, may increase the effect of the corticosteroid, prednisolone.
Quinidine barbiturateThe barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
RifampicinThe enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone.
Salicylate-sodiumThe corticosteroid, prednisolone, may decrease the effect of the salicylate, salicylate-sodium.
SalsalateThe corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate.
SecobarbitalThe barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisolone.
TacrineTacrine and Prednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
TalbutalThe barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisolone.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trisalicylate-cholineThe corticosteroid, prednisolone, may decrease the effect of the salicylate, trisalicylate-choline.
VecuroniumVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
WarfarinThe corticosteroid, prednisolone, alters the anticoagulant effect of warfarin.
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. Epub 2009 May 28. Pubmed
  2. Boudinot FD, D’Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. Pubmed

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2A6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

1. Corticosteroid-binding globulin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Corticosteroid-binding globulin P08185 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. Pubmed
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. Pubmed
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

1. Solute carrier organic anion transporter family member 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. Pubmed

2. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. Pubmed
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12